dc.contributor.author | Andtbacka, RHI | |
dc.contributor.author | Agarwala, SS | |
dc.contributor.author | Ollila, DW | |
dc.contributor.author | Hallmeyer, S | |
dc.contributor.author | Milhem, M | |
dc.contributor.author | Amatruda, T | |
dc.contributor.author | Nemunaitis, JJ | |
dc.contributor.author | Harrington, KJ | |
dc.contributor.author | Chen, L | |
dc.contributor.author | Shilkrut, M | |
dc.contributor.author | Ross, M | |
dc.contributor.author | Kaufman, HL | |
dc.date.accessioned | 2016-08-26T15:14:52Z | |
dc.date.issued | 2016-12-01 | |
dc.identifier.citation | Head & neck, 2016, 38 (12), pp. 1752 - 1758 | |
dc.identifier.issn | 1043-3074 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/75 | |
dc.identifier.eissn | 1097-0347 | |
dc.identifier.doi | 10.1002/hed.24522 | |
dc.description.abstract | BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). METHODS: Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma given talimogene laherparepvec (n = 61) or GM-CSF (n = 26). Outcomes were compared between talimogene laherparepvec and GM-CSF treated patients with cutaneous head and neck melanoma. RESULTS: DRR was higher for talimogene laherparepvec-treated patients than for GM-CSF treated patients (36.1% vs 3.8%; p = .001). A total of 29.5% of patients had a complete response with talimogene laherparepvec versus 0% with GM-CSF. Among talimogene laherparepvec-treated patients with a response, the probability of still being in response after 12 months was 73%. Median overall survival (OS) was 25.2 months for GM-CSF and had not been reached with talimogene laherparepvec. CONCLUSION: Treatment with talimogene laherparepvec was associated with improved response and survival compared with GM-CSF in patients with cutaneous head and neck melanoma. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1752-1758, 2016. | |
dc.format | Print-Electronic | |
dc.format.extent | 1752 - 1758 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Melanoma | |
dc.subject | Head and Neck Neoplasms | |
dc.subject | Skin Neoplasms | |
dc.subject | Neoplasm Invasiveness | |
dc.subject | Granulocyte-Macrophage Colony-Stimulating Factor | |
dc.subject | Neoplasm Staging | |
dc.subject | Prognosis | |
dc.subject | Disease-Free Survival | |
dc.subject | Treatment Outcome | |
dc.subject | Injections, Intralesional | |
dc.subject | Multivariate Analysis | |
dc.subject | Proportional Hazards Models | |
dc.subject | Survival Analysis | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Oncolytic Virotherapy | |
dc.subject | Kaplan-Meier Estimate | |
dc.title | Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-05-16 | |
rioxxterms.versionofrecord | 10.1002/hed.24522 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2016-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Head & neck | |
pubs.issue | 12 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
pubs.publication-status | Published | |
pubs.volume | 38 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Targeted Therapy | |
dc.contributor.icrauthor | Harrington, Kevin | |